Traders Hedging Record Rally Dabble in Exotic Options
The High Costs of Trump's 'Big Beautiful' New Car Loan Deduction
Can This Bridge Ease the Troubled US-Canadian Relationship?
Budapest's Most Historic Site Gets a Controversial Rebuild
Trump Administration Sues NYC Over Sanctuary City Policy
The steady grind higher in the S&P 500 Index has pushed most gauges of implied and realized volatility to the lowest levels in months — in some cases years. The collapse in volatility after the April tariff shock has surprised many investors, given the geopolitical tensions and uncertainty around the impact of levies on corporate earnings.
With a whiff of complacency in the market and a resurgence of meme-stock mania signaling euphoria among investors, strategists across Wall Street are talking more about picking up some protection against a retreat from the highs. Hedging is likely to gain traction both in the context of upcoming earnings and tariff deadlines, and the seasonal trend for the Cboe Volatility Index to rise through the third quarter from July lows.
But simple strategies can be tricky in a rising market, where the few, small dips are seen as buying opportunities. Vanilla put options quickly fall out of the money as the index rises, forcing investors to keep shifting positions higher to maintain their desired level of downside protection.
So strategists are pitching over-the-counter alternatives. At UBS Group AG and JPMorgan Chase & Co., they have recently recommended so-called lookback or re-settable put options, where the strike follows the market higher and — in the case of lookback puts — is set at the highest closing print during the life of the trade. Those are currently trading at a historically narrow premium to vanilla puts, JPMorgan strategists including Bram Kaplan wrote in a note earlier this month.
'Hedging is very much in focus,' said Antoine Porcheret, head of institutional structuring for the UK, Europe, Middle East and Africa at Citigroup Inc. 'We have seen decent buying flows in the lookback put as it is cheap by historical standards since the value of the lookback feature is a function of implied volatility, which is low.'
UBS strategist Kieran Diamond wrote in note last week that historically, a market on the highs is more likely to go higher than reverse, thus increasing the chance of a vanilla put struck today becoming deeper out of the money.
A lookback put implemented from a market high would have shifted the strike of a two-month put at 95% of the spot level 3.4% higher on average over the past 10 years, and the lookback feature costs only 0.4% more than the vanilla put, he said.
The best scenario to buy a lookback put is when the market rallies and then collapses. In such cases, the additional payoff versus the vanilla version can be significant.
'There was a wave of interest in the lookback hedge payoff earlier in the year, when spot was near highs and vols had dropped towards lows,' said Pete Clarke, UBS's global head of volatility strategy. 'Following the latest rally and vol reset, we've seen them actively quoted once again.'
S&P 500 futures were 0.2% higher as of 6:40 a.m. New York time on Monday.
Markets get another test in the coming week with the Federal Reserve rate decision, US employment and gross domestic product data, and the tariff deadline — plus a slew of big tech earnings.
Meanwhile, the re-emergence this month of wild swings in meme stocks will also likely have institutional investors reaching for protection trades, rather than chasing further gains. In 2021, retail-frenzied gains marked a spurt of euphoria for stocks, with moves that quickly faded.
The interest in lookback puts 'is mostly from accounts other than hedge funds, such as long-only asset managers and private banks,' Porcheret said. 'Hedge funds and especially volatility-arbitrage accounts tend to opt for cheapened downside structures as opposed to a lookback which carries additional cost.'
Volatility on technology stocks has been hit especially hard, with Asym 500 founder Rocky Fishman pointing out in a note last week that 10-day realized volatility on the Nasdaq 100 Index had fallen to the lowest level since 2021.
'Nasdaq and generally Tech has been a popular underlying as the volatility there has been especially crushed,' Porcheret said.
(Updates with S&P 500 futures in 11th paragraph. An earlier version corrected spelling of firm name in penultimate paragraph.)
Burning Man Is Burning Through Cash
It's Not Just Tokyo and Kyoto: Tourists Descend on Rural Japan
Elon Musk's Empire Is Creaking Under the Strain of Elon Musk
Confessions of a Laptop Farmer: How an American Helped North Korea's Wild Remote Worker Scheme
Scottish Wind Farms Show How to Counter Nimby Opposition
©2025 Bloomberg L.P.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 minutes ago
- Yahoo
Revolution Medicines to Report Financial Results for Second Quarter 2025 After Market Close on August 6, 2025
REDWOOD CITY, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the second quarter of 2025 on Wednesday, August 6, 2025, after market close. At 4:30 p.m. ET that day (1:30 p.m. PT), members of Revolution Medicines' senior management team will host a webcast to discuss the financial results for the quarter and provide an update on corporate progress. To listen to the live webcast, or access the archived webcast, please visit: Following the live webcast, a replay will be available on the company's website for at least 14 days. About Revolution Medicines, Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; and zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor, are currently in clinical development. The company anticipates that RMC-5127, a RAS(ON) G12V-selective inhibitor, will be its next RAS(ON) inhibitor to enter clinical development. Additional development opportunities in the company's pipeline focus on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C). For more information, please visit and follow us on LinkedIn. Revolution Medicines Media & Investor Contact:media@
Yahoo
8 minutes ago
- Yahoo
Board Declares Quarterly Dividend and Elects New Officer
WESTMINSTER, Colo., July 30, 2025 /PRNewswire/ -- Ball Corporation's (NYSE: BALL) board of directors (the "Board") today declared a cash dividend of 20 cents per share, payable September 16, 2025, to shareholders of record as of September 2, 2025. The Board also elected Edmund "Ted" Doering to serve as Chief Information Officer (CIO) of the corporation. Ted recently joined Ball to succeed Brian Gabbard, who is planning to retire from the company at the end of September. Ted brings more than three decades of global IT leadership experience, most recently serving as executive vice president and CIO at Berry Global. Before joining Berry, Ted was Chief Digital Officer at Emerson Electric and CIO of Emerson Automation Solutions. Ted has deep expertise in driving value creation, delivery execution and enterprise risk management. Conference Call Details Ball will announce its second quarter 2025 earnings on Tuesday, August 5, 2025 before trading begins on the New York Stock Exchange. At 9 a.m. Mountain Time on that day (11 a.m. Eastern Time), Ball will hold its regular quarterly conference call on the company's results and performance. Please use the following URL to join via webcast: To participate in the live call Q&A session, North American callers should use the following number, 877-497-9071. International callers should use the following number, +1 201-689-8727. For those unable to listen to the live call, a taped replay and transcript of the event will be available within 48 hours on Ball's website at under "Financial Results." About Ball Corporation Ball Corporation supplies innovative, sustainable aluminum packaging solutions for beverage, personal care and household products customers. Ball Corporation employs 16,000 people worldwide and reported 2024 net sales of $11.80 billion, which excludes the divested aerospace business. For more information, visit or connect with us on LinkedIn or Instagram. View original content to download multimedia: SOURCE Ball Corporation Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Yahoo
8 minutes ago
- Yahoo
Everest Group: Q2 Earnings Snapshot
HAMILTON, Bermuda (AP) — HAMILTON, Bermuda (AP) — Everest Group, Ltd. (EG) on Wednesday reported second-quarter net income of $680 million. The Hamilton, Bermuda-based company said it had net income of $16.10 per share. Earnings, adjusted for non-recurring costs, were $17.36 per share. The results topped Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment Research was for earnings of $15.14 per share. The reinsurance company posted revenue of $4.49 billion in the period, which also topped Street forecasts. Five analysts surveyed by Zacks expected $4.4 billion. _____ This story was generated by Automated Insights ( using data from Zacks Investment Research. Access a Zacks stock report on EG at Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data